Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)
Bleeding Outcomes Following Oral Soft Tissue Biopsy in Patients Receiving Direct Oral Anticoagulants
University of Pisa
100 participants
Apr 1, 2026
OBSERVATIONAL
Conditions
Summary
Direct oral anticoagulants (DOACs) are increasingly used, but evidence on bleeding risk during oral soft tissue biopsy is limited. This prospective case-control study compared intraoperative, perioperative, and postoperative bleeding in 50 patients on uninterrupted DOAC therapy versus 50 anticoagulant-naive controls undergoing standardized oral soft tissue biopsy with suturing. All bleeding events were managed with local haemostatic measures. The study aims to determine whether DOAC continuation is safe for this procedure.
Eligibility
Inclusion Criteria2
- capacity to understand and sign informed consent;
- documented indication for oral soft tissue biopsy
Exclusion Criteria3
- inability to provide consent;
- congenital or acquired coagulopathy (including haemophilia, von Willebrand disease, thrombocytopenia, or hepatic cirrhosis);
- active antiplatelet therapy other than low-dose aspirin
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07520890